Comparison of the new atypical antipsychotics olanzapine and ICI 204,636 with clozapine on behavioural responses to the selective “D1-like” dopamine receptor agonist A 68930 and selective “D2-like” agonist RU 24213
- 1 March 1996
- journal article
- research article
- Published by Springer Nature in Psychopharmacology
- Vol. 124 (1-2) , 40-49
- https://doi.org/10.1007/bf02245604
Abstract
The effects of the putative atypical antipsychotics olanzapine and ICI 204,636 on behavioural responses to the selective “D2-like” dopamine receptor agonist RU 24213 and to the selective “D1-like” agonist A 68930 were compared with those of the prototype atypical antipsychotic clozapine, the selective D1-like antagonist SCH 23390 and the selective D2-like antagonist YM 09151-2. Olanzapine (0.4–2.0 mg/kg) and ICI 204,636 (4.0–36.0 mg/kg), like clozapine (4.0–36.0 mg/kg) and SCH 23390 (0.01–1.0 mg/kg), effected at best modest reduction in typical sniffing and locomotor responses and, with the exception of ICI 204,636, released episodes of atypical myoclonic jerking to RU 24213 (12.5 mg/kg); a high dose of olanzapine (10.0 mg/kg), like YM 09151-2 (0.005–0.5 mg/kg), blocked all responsivity to RU 24213. Conversely, olanzapine (0.4–2.0 mg/kg) and ICI 204,636 (4.0–36.0 mg/kg), like clozapine (4.0–12.0 mg/kg) and SCH 23390 (0.01–0.1 mg/kg), readily blocked typical grooming responses to A 68930 (0.5 mg/kg); YM 09151-2 failed to block grooming and exerted more variable effects. Olanzapine and, to a lesser extent, ICI 204,636 share with clozapine a preferential action to attenuate D1-mediated function; given their lack of selective affinity for D1-like receptors, this common effect may be exerted at an alternative level of synaptic function. The action of olanzapine and particularly ICI 204,636 to release additional episodes of atypical vacuous chewing to A 68930 indicates some deviation from a wholly clozapine-like profile, the clinical significance of which remains to be specified.Keywords
This publication has 46 references indexed in Scilit:
- A multicentre, double-blind, placebo-controlled comparison of low and high dosage regimens of SeroquelTM in the treatment of hospitalised patients with acute exacerbation of subchronic or chronic schizophreniaEuropean Neuropsychopharmacology, 1994
- Efficacy of olanzapine in the positive and negative symptoms of schizophreniaEuropean Neuropsychopharmacology, 1994
- Mechanisms of action of atypical antipsychotic drugs: Implications for novel therapeutic strategies for schizophreniaSchizophrenia Research, 1991
- Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapineNature, 1991
- Dopamine receptor subtypes: beyond the D1/D2 classificationTrends in Pharmacological Sciences, 1990
- Evidence for Different States of the Dopamine Dl Receptor: Clozapine and Fluperlapine May Preferentially Label an Adenylate Cyclase-Coupled State of the Dl ReceptorJournal of Neurochemistry, 1986
- Inhibition of SKF 38393- and pergolide-induced circling in rats with unilateral 6-OHDA lesion is correlated to dopamine D-1 and D-2 receptor affinitiesin vitroJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1986
- Selective dopamine D2 receptor reduction enhances A D1 mediated oral dyskinesia in ratsLife Sciences, 1986
- Induction of oral dyskinesias in naive rats by D1 stimulationLife Sciences, 1983
- Activity of two new potent dopaminergic agonists at the striatal and anterior pituitary levelsNeuropharmacology, 1980